CD163 and metabolic dysfunction-associated steatotic liver disease: The group treated with the anti-CD163-dexamethasone conjugate showed strongly reduced values of all analyzed histological liver lesion parameters (steatosis, inflammation, hepatocyte ballooning, fibrosis, and glycogen accumulation) contributing to NASH, relative to the placebo control; accordingly, the NAFLD activity score (NAS) (steatosis, hepatocyte ballooning, and inflammation) was significantly reduced, whereas no effect was seen in rats treated with free dexamethasone (Figure 4; Table 2).